Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients

Liver Transplantation

Volumn 15, Issue 2, 2009, Pages 136-147

  Nashan, Bjöm ^a   Saliba, Faouzi ^b   Durand, Francois ^c   Barcéna, Rafael ^d   Herrero, Jose Ignacio ^e   Mentha, Gilles ^f   Neuhaus, Peter ^g   Bowles, Matthew ^h   Patch, David ⁱ   Bernardos, Angel ^j   Klempnauer, Jürgen ^k   Bouw, René ^l   Ives, Jane ^l   Mamelok, Richard ^m   McKay, Diane ^l   Truman, Matt ⁿ   Marotta, Paul ^o  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HÔPITAL PAUL BROUSSE   (France)

^c BEAUJON HOSPITAL   (France)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l ROCHE PRODUCTS LTD   (United Kingdom)

^m Mamelok Consulting   (United States)

ⁿ Roche Products Pty Ltd   (Australia)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRAIN DISEASE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT FAILURE; GRAFT RECIPIENT; HEADACHE; HEPATITIS C; HEPATOBILIARY DISEASE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; IATROGENIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSOMNIA; INTERCURRENT ILLNESS; LEUKOPENIA; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPENIA; PNEUMOCYSTOSIS; POSTPROCEDURAL PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT VIRUS INFECTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VIREMIA;

ADMINISTRATION, ORAL; ADULT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TREATMENT OUTCOME;

EID: 67649228624     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21657     Document Type: Article

References (31)

1. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110-1115.
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-428.
3. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360:1119-1125.
4. Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998;65:180-187.
5. Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998;66:1395-1398.
6. Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML, Sterling RK, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:463-472.
7. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11:750-759.
8. Bullingham RE. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455.
9. Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007;13: 791-796.
10. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999;21:536-539.
11. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225-232.
12. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100-104.
13. Vidal E, Cantarell C, Capdevila L, Monforte V, Roman A, Pou L. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol 2000;87:182-184.
14. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-128.
15. Kobayashi M, Saitoh H, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004;309:1029-1035.
16. Hesselink DA, van Hest RM, Mathot RA, Bonthius F, Weimar W, de Bruin RW, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005;5:987-994.
17. Pou L, Brunet M, Cantarell C, Vidal E, Oppenheimer F, Monforte V, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 2001; 23:35-38.
18. Gregoor PJ, de Sevaux RG, Hene RJ, Hilbrands LB, Vos P, van Gelder T, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68:1603-1606.
19. Hesselink D, van Gelder T. The influence of cyclosporine on mycophenolic acid plasma concentrations: a review. Transplant Rev 2003;17:158-163.
20. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003;43:866-880.
21. Hohage H, Zeh M, Heck M, Gerhardt UW, Welling U, Suwelack BM. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc 2005;37:1748-1750.
22. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41:268-276.
23. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001;34:17-22.
24. Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Ollerich M, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003;25: 609-622.
25. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-1017.
26. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999;21:498-506.
27. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38:268-275.
28. Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998;66:1616-1621.
29. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442-450.
30. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998;66:493-499.
31. Paterson DL, Singh N, Panebianco A, Wannstedt MM, Wagener MM, Gayowski T, Marino IR. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998;66:593-598.